在甲型流感病毒感染期间,自然衍生的细胞因子肽限制病毒复制和严重疾病

IF 4.6 2区 医学 Q2 IMMUNOLOGY Clinical & Translational Immunology Pub Date : 2023-03-23 DOI:10.1002/cti2.1443
Christopher M Harpur, Alison C West, Mélanie A Le Page, Maggie Lam, Christopher Hodges, Osezua Oseghale, Andrew J Gearing, Michelle D Tate
{"title":"在甲型流感病毒感染期间,自然衍生的细胞因子肽限制病毒复制和严重疾病","authors":"Christopher M Harpur,&nbsp;Alison C West,&nbsp;Mélanie A Le Page,&nbsp;Maggie Lam,&nbsp;Christopher Hodges,&nbsp;Osezua Oseghale,&nbsp;Andrew J Gearing,&nbsp;Michelle D Tate","doi":"10.1002/cti2.1443","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Novel host-targeted therapeutics could treat severe influenza A virus (IAV) infections, with reduced risk of drug resistance. LAT8881 is a synthetic form of the naturally occurring C-terminal fragment of human growth hormone. Acting independently of the growth hormone receptor, it can reduce inflammation-induced damage and promote tissue repair in an animal model of osteoarthritis. LAT8881 has been assessed in clinical trials for the treatment of obesity and neuropathy and has an excellent safety profile. We investigated the potential for LAT8881, its metabolite LAT9991F and LAT7771 derived from prolactin, a growth hormone structural homologue, to treat severe IAV infection.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>LAT8881, LAT9991F and LAT7771 were evaluated for their effects on cell viability and IAV replication <i>in vitro</i>, as well as their potential to limit disease in a preclinical mouse model of severe IAV infection.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p><i>In vitro</i> LAT8881 treatment enhanced cell viability, particularly in the presence of cytotoxic stress, which was countered by siRNA inhibition of host lanthionine synthetase C-like proteins. Daily intranasal treatment of mice with LAT8881 or LAT9991F, but not LAT7771, from day 1 postinfection significantly improved influenza disease resistance, which was associated with reduced infectious viral loads, reduced pro-inflammatory cytokines and increased abundance of protective alveolar macrophages. LAT8881 treatment in combination with the antiviral oseltamivir phosphate led to more pronounced reduction in markers of disease severity than treatment with either compound alone.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These studies provide the first evidence identifying LAT8881 and LAT9991F as novel host-protective therapies that improve survival, limit viral replication, reduce local inflammation and curtail tissue damage during severe IAV infection. Evaluation of LAT8881 and LAT9991F in other infectious and inflammatory conditions of the airways is warranted.</p>\n </section>\n </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"12 3","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1443","citationCount":"3","resultStr":"{\"title\":\"Naturally derived cytokine peptides limit virus replication and severe disease during influenza A virus infection\",\"authors\":\"Christopher M Harpur,&nbsp;Alison C West,&nbsp;Mélanie A Le Page,&nbsp;Maggie Lam,&nbsp;Christopher Hodges,&nbsp;Osezua Oseghale,&nbsp;Andrew J Gearing,&nbsp;Michelle D Tate\",\"doi\":\"10.1002/cti2.1443\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>Novel host-targeted therapeutics could treat severe influenza A virus (IAV) infections, with reduced risk of drug resistance. LAT8881 is a synthetic form of the naturally occurring C-terminal fragment of human growth hormone. Acting independently of the growth hormone receptor, it can reduce inflammation-induced damage and promote tissue repair in an animal model of osteoarthritis. LAT8881 has been assessed in clinical trials for the treatment of obesity and neuropathy and has an excellent safety profile. We investigated the potential for LAT8881, its metabolite LAT9991F and LAT7771 derived from prolactin, a growth hormone structural homologue, to treat severe IAV infection.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>LAT8881, LAT9991F and LAT7771 were evaluated for their effects on cell viability and IAV replication <i>in vitro</i>, as well as their potential to limit disease in a preclinical mouse model of severe IAV infection.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p><i>In vitro</i> LAT8881 treatment enhanced cell viability, particularly in the presence of cytotoxic stress, which was countered by siRNA inhibition of host lanthionine synthetase C-like proteins. Daily intranasal treatment of mice with LAT8881 or LAT9991F, but not LAT7771, from day 1 postinfection significantly improved influenza disease resistance, which was associated with reduced infectious viral loads, reduced pro-inflammatory cytokines and increased abundance of protective alveolar macrophages. LAT8881 treatment in combination with the antiviral oseltamivir phosphate led to more pronounced reduction in markers of disease severity than treatment with either compound alone.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>These studies provide the first evidence identifying LAT8881 and LAT9991F as novel host-protective therapies that improve survival, limit viral replication, reduce local inflammation and curtail tissue damage during severe IAV infection. Evaluation of LAT8881 and LAT9991F in other infectious and inflammatory conditions of the airways is warranted.</p>\\n </section>\\n </div>\",\"PeriodicalId\":152,\"journal\":{\"name\":\"Clinical & Translational Immunology\",\"volume\":\"12 3\",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2023-03-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1443\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cti2.1443\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cti2.1443","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 3

摘要

新的宿主靶向治疗方法可以治疗严重甲型流感病毒(IAV)感染,并降低耐药风险。LAT8881是天然存在的人类生长激素c端片段的合成形式。在骨关节炎动物模型中,它可以独立于生长激素受体起作用,减少炎症引起的损伤,促进组织修复。LAT8881已在治疗肥胖和神经病变的临床试验中进行评估,并具有良好的安全性。我们研究了LAT8881及其代谢物LAT9991F和LAT7771衍生自催乳素(一种生长激素结构同源物)治疗严重IAV感染的潜力。方法研究LAT8881、LAT9991F和LAT7771对体外IAV复制和细胞活力的影响,以及在严重IAV感染的临床前小鼠模型中对疾病的限制作用。结果在体外,LAT8881处理提高了细胞活力,特别是在细胞毒性应激存在的情况下,这可以通过siRNA抑制宿主硫氨酸合成酶c样蛋白来抵消。从感染后第1天起,每天用LAT8881或LAT9991F(而不是LAT7771)鼻内治疗小鼠,可显著提高流感疾病的抵抗力,这与感染病毒载量降低、促炎细胞因子减少和保护性肺泡巨噬细胞丰度增加有关。与单独使用任何一种化合物治疗相比,LAT8881与抗病毒药物磷酸奥司他韦联合治疗导致疾病严重程度标志物的显著降低。结论这些研究首次证明了LAT8881和LAT9991F是一种新的宿主保护疗法,可提高严重IAV感染期间的生存率、限制病毒复制、减轻局部炎症和减少组织损伤。评估LAT8881和LAT9991F在其他气道感染和炎症条件下是有必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Naturally derived cytokine peptides limit virus replication and severe disease during influenza A virus infection

Objectives

Novel host-targeted therapeutics could treat severe influenza A virus (IAV) infections, with reduced risk of drug resistance. LAT8881 is a synthetic form of the naturally occurring C-terminal fragment of human growth hormone. Acting independently of the growth hormone receptor, it can reduce inflammation-induced damage and promote tissue repair in an animal model of osteoarthritis. LAT8881 has been assessed in clinical trials for the treatment of obesity and neuropathy and has an excellent safety profile. We investigated the potential for LAT8881, its metabolite LAT9991F and LAT7771 derived from prolactin, a growth hormone structural homologue, to treat severe IAV infection.

Methods

LAT8881, LAT9991F and LAT7771 were evaluated for their effects on cell viability and IAV replication in vitro, as well as their potential to limit disease in a preclinical mouse model of severe IAV infection.

Results

In vitro LAT8881 treatment enhanced cell viability, particularly in the presence of cytotoxic stress, which was countered by siRNA inhibition of host lanthionine synthetase C-like proteins. Daily intranasal treatment of mice with LAT8881 or LAT9991F, but not LAT7771, from day 1 postinfection significantly improved influenza disease resistance, which was associated with reduced infectious viral loads, reduced pro-inflammatory cytokines and increased abundance of protective alveolar macrophages. LAT8881 treatment in combination with the antiviral oseltamivir phosphate led to more pronounced reduction in markers of disease severity than treatment with either compound alone.

Conclusion

These studies provide the first evidence identifying LAT8881 and LAT9991F as novel host-protective therapies that improve survival, limit viral replication, reduce local inflammation and curtail tissue damage during severe IAV infection. Evaluation of LAT8881 and LAT9991F in other infectious and inflammatory conditions of the airways is warranted.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical & Translational Immunology
Clinical & Translational Immunology Medicine-Immunology and Allergy
CiteScore
12.00
自引率
1.70%
发文量
77
审稿时长
13 weeks
期刊介绍: Clinical & Translational Immunology is an open access, fully peer-reviewed journal devoted to publishing cutting-edge advances in biomedical research for scientists and physicians. The Journal covers fields including cancer biology, cardiovascular research, gene therapy, immunology, vaccine development and disease pathogenesis and therapy at the earliest phases of investigation.
期刊最新文献
Autologous Epstein-Barr virus-specific adoptive T-cell therapy in a patient with lupus nephritis. The contribution of the CRP/CD64 axis to renal cancer progression by inducing protumor activation of tumor-associated macrophages. Natural killer cell antibody-dependent cellular cytotoxicity to Plasmodium falciparum is impacted by cellular phenotypes, erythrocyte polymorphisms, parasite diversity and intensity of transmission Naturally acquired adaptive immunity to Streptococcus pneumoniae is impaired in rheumatoid arthritis patients Inhibitory effect of hydroxychloroquine on glucocorticoid-induced osteoporosis in lupus therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1